SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
SPRC stock price ended at $1.07 on 金曜日, after rising 1.90%
On the latest trading day Jan 16, 2026, the stock price of SPRC rose by 1.90%, climbing from $1.02 to $1.07. Throughout the session, the stock experienced a volatility of 15.84%, with prices fluctuating between a daily low of $1.01 and a high of $1.17. Alongside this price increase, trading volume also rose by 91.0K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 357.4K shares were traded, amounting to a market value of approximately $3.5M.